The growth potential of the weight-loss market could explode with advances, notably GLP-1 pills, and broader insurance ...

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

At the end of the day, GLP-1s can be a powerful tool for achieving your weight loss goals, but only if they're safe and ...

Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection ...

The pills are expected to cost much less then shots of blockbuster drugs like Zepbound and Wegovy. Mr. Funk was the managing ...

People who switched to the experimental daily GLP-1 pill orforglipron were able to maintain their weight loss after stopping ...

Topline data from the phase 3 ATTAIN-MAINTAIN trial evaluated orforglipron for weight maintenance after initial treatment with Wegovy or Zepbound in adults with obesity or overweight.

Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.

Below is a comparison of today’s most prescribed GLP-1 medications, including Ozempic and Trulicity, both widely used for ...

The average participant getting a 12-mg weekly injection lost 71 pounds in 68 weeks.  "This is beyond what we see with any ...

Bank of America reaffirmed its Buy rating for Eli Lilly, setting a price target of $1,268. Analyst Jason Gerberry noted that the trial data strengthens the company's competitive stance against rival ...

Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug.